Singapore-based deep tech investor Vickers Venture Partners’s first $120 million special purpose acquisition company (SPAC), Vickers Vantage Corp I, is merging with Scilex Holding Company, a biopharmaceutical firm developing non-opioid therapies for patients.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
